The Sage Group

Peripheral Arterial Disease (PAD) Interventional Market Analysis. Based on Potential Treatment with Perioperative Oral Antiplatelet Therapy

This report is one of three new publications that examine interventional procedures employed to treat lower limb arterial disease. Procedures include revascularization with surgery or endovascular devices, as well as amputation.

Employing ICD-9 procedure data, PAD Interventional Market Analysis Based on Treatment with Perioperative Oral Antiplatelet Therapy provides a comprehensive examination of the following topics: an overview of the 2005 inpatient interventional market by type of procedure and vascular territory; an in-depth analysis of 2005 revascularization procedures considered suitable for treatment with perioperative oral antiplatelet therapy in the aortoiliac, femoropopliteal and tibioperoneal regions; an examination of amputation by type of procedure and territory; an analysis of inpatient and outpatient endovascular procedures by type and vascular territory and forecasts of endovascular procedures through 2020 by device type and territory.

Since the endovascular market is considered from the viewpoint of the number of procedures per disease occurrence (a rough proxy for patients), the detailed market analyses are based on primary stents only. For comparative purposes, overviews of the endovascular market including provisional stents and the interventional market with provisional stents by type of procedure are included. In addition, an analysis of inpatient primary and provisional stenting by type and territory is provided.

The report features extensive annual data, including the number of people in the U.S. with PAD in the 2000-2020 periods and the U.S. PAD revascularization market for surgical and endovascular procedures in the 2000-2020 periods. Based on two alternative technological scenarios, angioplasty/atherectomy and primary stent procedures are projected through 2020 in the aortoiliac, femoropopliteal and tibioperoneal vascular regions. The optimistic case reflects primary stenting gaining share, while in the pessimistic case primary stenting declines.

An evaluation of the dollar value of the current endovascular device market is also included, which features a comparison of size and share by device type in 1997, 2003 and 2005.

A detailed analysis of the market including both primary and provisional stents is the topic of the first report in this series, PAD Interventional Market Analysis Based on Treatment with Primary and Provisional Stents.

Price: $4,400

To purchase call us at 404 520-6652 or

Contact yost@thesagegroup.us